Hangzhou Biotest Biotech Co.,Ltd.
688767
Rank in Stocks
#8946
Hangzhou Biotest Biotech Co., LTD. is an enterprise focused on the research,... Hangzhou Biotest Biotech Co., LTD. is an enterprise focused on the research, development, manufacturing, sales, and servicing of in vitro diagnostic (IVD) solutions. Operating both domestically within China and across international markets, the company provides a comprehensive range of medical testing products. Their offerings span crucial health areas including reproductive health, cancer detection, cardiovascular conditions, inflammatory markers, biochemical analysis, and various infectious diseases. This extensive portfolio also encompasses rapid diagnostic tests for COVID-19 (covering both antibody and antigen detection), as well as screening kits for drug use (utilizing urine, saliva, and hair samples) and assessing vitamin D levels. Beyond diagnostic kits and reagents, Hangzhou Biotest Biotech also supplies essential accompanying equipment, such as immunochromatography readers and fluorescence immunoassay quantitative analyzers. The company, established in 2008, is based in Hangzhou, China.
Share Price
$5.89
Last synced: 2026-11-13
Market Cap
$905.28M
Change (1 day)
1.10%
Change (1 year)
8.84%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Hangzhou Biotest Biotech Co.,Ltd. (688767)
Category
Healthcare
EPS for Hangzhou Biotest Biotech Co.,Ltd. (688767)
EPS as of September 2026 TTM: $0.02
According to Hangzhou Biotest Biotech Co.,Ltd.'s latest financial reports, its current EPS (TTM) is $0.02. At the end of 2025 the company had an EPS of $0.05, a decrease compared to its 2024 EPS of $0.16.
EPS history for Hangzhou Biotest Biotech Co.,Ltd. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.02 | -64.00% |
| 2025 | $0.05 | -71.00% |
| 2024 | $0.16 | 57.13% |
| 2023 | $0.10 | -86.64% |
| 2022 | $0.75 | -30.52% |
| 2021 | $1.08 | 81.51% |
| 2020 | $0.60 | 1,558.77% |
| 2019 | $0.04 | 45.34% |
| 2018 | $0.02 | 349.09% |
| 2017 | $0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -5,044.44% |
US
|
|
| $15.66 | 86,900.00% |
US
|
|
| $-7.07 | -39,377.78% |
US
|
|
| $-5.29 | -29,488.89% |
AU
|
|
| $12.73 | 70,634.44% |
BE
|
Questions about Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS)
What is Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS)?
Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS) over the last twelve months is $0.02, as of Sep 2026.
What was Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS) in 2025?
In 2025, Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS) was $0.05, 68.75% less than in 2024 ($0.16).
How has Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS) went from $0.60 to $0.05, an average decline of 39.16% a year.
How does Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS) compare with similar companies?
Hangzhou Biotest Biotech Co.,Ltd.'s earnings per share (EPS) ($0.02) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.